Defatting strategies in the current era of liver steatosis

Laura Ioana Mazilescu; Markus Selzner; Nazia Selzner

doi:10.1016/j.jhepr.2021.100265

Defatting strategies in the current era of liver steatosis

JHEP Rep. 2021 Mar 13;3(3):100265. doi: 10.1016/j.jhepr.2021.100265. eCollection 2021 Jun.

Authors

Laura Ioana Mazilescu^{1

2

3}, Markus Selzner¹, Nazia Selzner¹

Affiliations

¹ Ajmera Transplant Program, Toronto General Hospital, Ontario, Canada.
² Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada.
³ Department of General, Visceral, and Transplantation Surgery, University Hospital Essen, Essen, Germany.

Abstract

Liver steatosis is emerging as a major cause of chronic liver disease worldwide, mainly due to the increasing rate of obesity, type 2 diabetes, and metabolic syndrome. Because of the increased incidence of liver steatosis, many organs are currently declined for transplantation despite high demand and waiting list mortality. Defatting strategies have recently emerged as a means of rapidly reducing liver steatosis to expand the pool of available organs. This review summarises advances in defatting strategies in experimental and human models of liver steatosis over the last 20 years.

Keywords: GDNF, glial cell-line derived neurotrophic factor; HFD, high-fat diet; HIEC, hepatic endothelial cells; HOPE, hypothermic machine perfusion; LDs, lipid droplets; Macrosteatosis; NAFL, non-alcoholic fatty liver; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NEsLP, normothermic ex situ machine perfusion; PHHs, primary human hepatocytes; PPAR, peroxisome proliferator-activated receptor; PXR, pregnane X receptor; SCS, static cold storage; SRS, steatosis reduction supplements; TG, triglyceride; ischemia-reperfusion injury; liver transplantation; machine perfusion.

Publication types

Review